

## **Supplementary Appendix 7: Research Agenda**

### **2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis (JIA): Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint (TMJ) Arthritis and Systemic JIA**

These recommendations in conjunction with those published in 2019 were intended to be a “complete” coverage of the treatment of management of persons with JIA. During the writing of these recommendations, several areas for exploration were noted by patients/parents and investigators. In addition, the low level of evidence clearly pointed to necessary studies for the future.

1. Filling in evidentiary gap
2. Head to head trials of nb and bDMARDs within and across class of medication
3. bDMARD vs. nbDMARD for TMJ arthritis
4. Frequency and type of screening for mental health issues in JIA patients
5. Approach to tapering medications in remission: All subtypes
6. Diet: Role in treatment
7. Supplements: Role in treatment
8. Biosimilars: Use and monitoring
9. Exercise safety
10. Immunization safety: Clarity of risk of live virus vaccine by type of immunization